Search
Birmingham, AL Paid Clinical Trials
A listing of 967 clinical trials in Birmingham, AL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
253 - 264 of 967
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 967 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety and tolerability of:
* casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
* casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Recruiting
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Ps0039 50140, Birmingham, Alabama
Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
05/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Heart Failure
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
Recruiting
This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of Alabama, Birmingham, Alabama
Conditions: Prostate Carcinoma
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
Recruiting
This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: Alabama Clinical Therapeutics, Birmingham, Alabama
Conditions: Vertebral Compression Fracture, Compression Fracture, Vertebral Compression
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
Recruiting
The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes. The primary objective of this pilot study is to determine if anti-HTN treatment to BP\<130/80mmHg in pregnant patients with stage 1 HTN is associated with a difference in birthweight percentile at delivery. Patients with stage 1 hypertension in pregnancy will be randomized to BP goals of \<130/80m... Read More
Gender:
FEMALE
Ages:
Between 14 years and 89 years
Trial Updated:
05/27/2025
Locations: UAB, Birmingham, Alabama
Conditions: Hypertension in Pregnancy
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Systemic Lupus Erythematosus
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Recruiting
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Anemia, Sickle Cell, Healthy Volunteers
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/27/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/27/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Progressive Pulmonary Fibrosis
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Recruiting
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer.
Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cance... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Prostate Cancer
Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
Recruiting
Growth-restricted very preterm infants (VPT) are born without adequate fat mass (FM) deposits and low docosahexaenoic acid (DHA) concentrations. They often experience further declines in DHA concentrations during the initial three weeks post-birth while advancing enteral feeds and receiving lipid supplementation predominantly through parenteral nutrition. These suboptimal enteral and parenteral nutrition practices significantly heighten the risk of faltering postnatal growth. One promising appro... Read More
Gender:
ALL
Ages:
Between 24 hours and 72 hours
Trial Updated:
05/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Infant Malnutrition, Light-For-Dates With Signs of Fetal Malnutrition, Premature, Nutrition Disorder, Infant
253 - 264 of 967